unlocking value from innovation
Looking for assets?
At Willuhn Consulting, we regularly come across interesting early-stage projects. Through regular networking with academics and founders and long-term mentoring relationships, we get to know the people and their science well. That trust lets us help shape the pitch and the story over time: clarifying the problem to be solved and the solution proposed, sharpening the differentiation, and aligning the narrative with what biotech-focused VCs and corporate investors typically look for. It’s a journey, not a one-off. When a project is ready, we present these cases to investors as structured, early-stage opportunities.
Looking for a CMC expert?
A VC backs a promising asset, but the CMC and development plan feel undercooked. Hiring a full-time CMC lead is too early, too expensive, or not the right fit for this stage. Instead, they bring in Willuhn Consulting. We act as the experienced CMC voice for the asset or portfolio company: mapping out a realistic development path, planning clinical supply, engaging CDMOs and regulators, and preparing clear board and investor updates. We lay out what needs to happen now, what can wait, and where the real technical and schedule risks sit. The result is a sharper plan, fewer surprises, and a more credible story—without adding a full-time hire to the cap table.
Looking to buy?
When a PE firm or corporate buyer considers a carve-out, site acquisition, or platform purchase, technical and CMC risks can make or break the deal. At Willuhn Consulting, we support investors through this process: from initial due diligence to post-close integration and transition.
We assess the target’s capabilities, facilities, quality systems, and supply chain robustness. We identify what will be hard, expensive, or slow—and provide concrete, evidence-based plans to mitigate those risks. After close, we help integrate the asset into the buyer’s operations: aligning quality systems, managing CDMO transitions, and ensuring continuity of clinical or commercial supply. The result is a clearer view of value, fewer surprises post-deal, and a smoother path to execution.